EGFR and Granuloma: The drugs most often implicated in these effects were epidermal growth factor receptor (EGFR) inhibitors, represented by panitumumab, gefitinib, and erlotinib, responsible for 50% of ungual changes (paronychia, periungual granulomas, onycholysis, onychodystrophy, and onychocryptosis).